New cell therapy targets advanced sarcomas in early trial
NCT ID NCT07052383
First seen May 07, 2026 · Last updated May 07, 2026 · Updated 1 time
Summary
This early-stage study is testing a new treatment called DIT309 for people with advanced bone or soft tissue sarcomas that have not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) to attack the cancer. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Only 15 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.